Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 511: Pancytopenia with hypercellular bone marrow is seen in which of the following conditions?

A. Paroxysmal nocturnal hemoglobinuria (PNH)
B. Megaloblastic anemia (Correct Answer)
C. Acquired aplastic anemia
D. Thalassemia

Explanation: **Explanation:** The hallmark of **Megaloblastic Anemia** is "ineffective hematopoiesis." In this condition (usually due to Vitamin B12 or Folate deficiency), there is a defect in DNA synthesis while RNA synthesis remains intact. This leads to nuclear-cytoplasmic asynchrony, where cells grow large but cannot divide properly [1]. Consequently, the bone marrow is **hypercellular** because it is packed with megaloblasts, but these cells undergo intramedullary destruction (apoptosis) before reaching maturity. This results in a decrease in all three cell lines in the peripheral blood (**Pancytopenia**). **Analysis of Incorrect Options:** * **Paroxysmal Nocturnal Hemoglobinuria (PNH):** While PNH can present with pancytopenia, it is typically associated with a **hypocellular** marrow (often overlapping with Aplastic Anemia) or a normocellular marrow with erythroid hyperplasia if hemolysis is the primary feature. * **Acquired Aplastic Anemia:** This is the classic cause of pancytopenia, but the bone marrow is characteristically **hypocellular** (replaced by fat cells). * **Thalassemia:** This typically presents with microcytic hypochromic anemia and erythroid hyperplasia in the marrow, but it does not usually cause generalized pancytopenia. **High-Yield Clinical Pearls for NEET-PG:** * **Differential Diagnosis of Pancytopenia with Hypercellular Marrow:** Megaloblastic anemia, Myelodysplastic Syndrome (MDS), and Aleukemic Leukemia. * **Peripheral Smear:** Look for macro-ovalocytes and **hypersegmented neutrophils** (>5 lobes) [1]. * **Biochemical Markers:** Elevated LDH and Indirect Bilirubin (due to ineffective hematopoiesis/intramedullary hemolysis). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 593-594.

Question 512: What is the antibody responsible for heparin-induced thrombocytopenia?

A. Antiheparin/PF4 antibody (Correct Answer)
B. Antiheparin/PF2 antibody
C. Antiheparin/GP IIb/IIIa antibody
D. Antiheparin GP Ib/IX antibody

Explanation: ### Explanation **Heparin-Induced Thrombocytopenia (HIT)** is a life-threatening clinico-pathological syndrome caused by an immune response to heparin therapy. **1. Why Option A is correct:** The pathogenesis of HIT (specifically Type II) involves the formation of IgG antibodies against a complex of **Heparin and Platelet Factor 4 (PF4)**. PF4 is a cationic protein released from the alpha-granules of activated platelets. When heparin (anionic) binds to PF4, it creates a neoantigen. The resulting **IgG-Heparin-PF4 immune complexes** bind to the **FcγRIIa receptors** on the surface of platelets. This leads to: * **Platelet Activation:** Causing the release of procoagulant microparticles (leading to thrombosis). * **Platelet Consumption:** Leading to thrombocytopenia. **2. Why the other options are incorrect:** * **Option B (PF2):** Platelet Factor 2 is involved in fibrinogen sensitization but has no role in the pathogenesis of HIT. * **Option C (GP IIb/IIIa):** These are targets for antibodies in **Immune Thrombocytopenic Purpura (ITP)** and are the site of action for drugs like Abciximab. * **Option D (GP Ib/IX):** This is the Von Willebrand Factor (vWF) receptor. Deficiencies lead to **Bernard-Soulier Syndrome**, and it is also a target in some cases of ITP, but not HIT. **3. High-Yield Clinical Pearls for NEET-PG:** * **Timing:** Typically occurs **5–10 days** after starting heparin. * **Paradox:** Despite low platelet counts, HIT is a **pro-thrombotic state** (venous > arterial thrombosis). * **Diagnosis:** Screen with ELISA (high sensitivity); confirm with **Serotonin Release Assay (SRA)** (Gold Standard/High specificity). * **Management:** Immediately stop all heparin. Start alternative anticoagulants like **Argatroban** (Direct Thrombin Inhibitor) or Fondaparinux. Never give platelet transfusions as they "fuel the fire."

Question 513: Which of the following is a cause of extravascular hemolysis?

A. Falciparum malaria
B. Sickle cell disease (Correct Answer)
C. Mismatched blood transfusion
D. Microthrombi in circulation

Explanation: **Explanation:** Hemolysis is categorized into **intravascular** (destruction within blood vessels) and **extravascular** (destruction by macrophages in the spleen and liver). **1. Why Sickle Cell Disease (SCD) is correct:** In SCD, the substitution of valine for glutamic acid leads to HbS polymerization under deoxygenated conditions. This results in "sickling," which causes the red blood cell (RBC) membrane to become rigid and damaged. These deformed cells are recognized as abnormal by the **splenic sinusoids** and are sequestered and phagocytosed by **splenic macrophages**. This is the classic mechanism of **extravascular hemolysis**. (Note: Severe sickling crises can occasionally cause a minor component of intravascular hemolysis, but the primary mechanism is extravascular). **2. Analysis of Incorrect Options:** * **Falciparum Malaria:** Causes direct rupture of RBCs during the erythrocytic cycle and complement-mediated lysis, leading to significant **intravascular hemolysis** (Blackwater fever). * **Mismatched Blood Transfusion:** Acute hemolytic transfusion reactions (ABO incompatibility) involve IgM-mediated complement activation, leading to the formation of Membrane Attack Complexes (MAC) and immediate **intravascular hemolysis**. * **Microthrombi in circulation:** This describes **Microangiopathic Hemolytic Anemia (MAHA)**. RBCs are physically shredded as they pass through fibrin strands in small vessels (e.g., in DIC, HUS, or TTP), resulting in schistocytes and **intravascular hemolysis**. **NEET-PG High-Yield Pearls:** * **Extravascular Hemolysis:** Characterized by splenomegaly, jaundice (unconjugated), and increased risk of gallstones [1]. Examples: Hereditary Spherocytosis, Warm AIHA, Sickle Cell Anemia [2]. * **Intravascular Hemolysis:** Characterized by hemoglobinuria, hemosiderinuria, and decreased serum haptoglobin [3]. Examples: PNH, G6PD deficiency (acute), MAHA, and Malaria. * **Key Marker:** Low haptoglobin is seen in both, but is significantly more profound in intravascular hemolysis. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 602-603. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 651-652. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 642-643.

Question 514: In acute myeloid leukemia, Auer rods are numerous in which subtype?

A. M2
B. M3 (Correct Answer)
C. M4
D. M5

Explanation: In Acute Myeloid Leukemia (AML), **Auer rods** are needle-like, azurophilic cytoplasmic inclusions formed by the fusion of primary granules (lysosomes) containing peroxidase [1]. ### **Why M3 is the Correct Answer** **AML-M3 (Acute Promyelocytic Leukemia)** is characterized by a proliferation of abnormal promyelocytes [1]. These cells contain an abundance of primary granules, leading to the frequent formation of Auer rods. In M3, these rods are often found in clusters or bundles, referred to as **"faggot cells"** [3]. The massive release of these granules into the circulation often triggers **Disseminated Intravascular Coagulation (DIC)**, a critical clinical hallmark of this subtype [3]. ### **Why Other Options are Incorrect** * **M2 (AML with Maturation):** While Auer rods are commonly seen in M2, they are typically present as single, isolated rods rather than the "numerous" or bundled rods characteristic of M3 [3]. * **M4 (Acute Myelomonocytic Leukemia):** This subtype shows both granulocytic and monocytic differentiation. While Auer rods may be present in the granulocytic component, they are not a defining or "numerous" feature. * **M5 (Acute Monocytic Leukemia):** Auer rods are characteristically **absent** in pure monocytic lineages (M5a/M5b) [1]. ### **High-Yield Clinical Pearls for NEET-PG** * **Cytogenetics:** M3 is associated with **t(15;17)**, involving the *PML-RARA* fusion gene [2]. * **Treatment:** M3 is uniquely sensitive to **All-Trans Retinoic Acid (ATRA)** and Arsenic Trioxide. * **Staining:** Auer rods are strongly **Myeloperoxidase (MPO) positive**. * **Mnemonic:** "Faggot cells" = "Bundle of sticks" = M3. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 621-622. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-621. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 620.

Question 515: What is the definitive finding of G6PD deficiency?

A. Bite cells (Correct Answer)
B. Intravascular hemolysis
C. Splenomegaly
D. Hemoglobinuria

Explanation: **Explanation:** **Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency** is an X-linked recessive disorder where the lack of G6PD enzyme leads to decreased NADPH production, making erythrocytes vulnerable to oxidative stress (triggered by fava beans, infections, or drugs like Primaquine). **Why "Bite Cells" is the correct answer:** Under oxidative stress, hemoglobin denatures and precipitates into insoluble inclusions called **Heinz bodies**. As these RBCs pass through the splenic sinusoids, splenic macrophages "pluck out" these inclusions [1]. This process leaves a characteristic semicircular defect in the RBC membrane, resulting in **Bite cells (Degmacytes)** [1]. These are the hallmark morphological finding on a peripheral smear during an acute hemolytic episode. **Analysis of Incorrect Options:** * **B. Intravascular hemolysis:** While G6PD deficiency causes both intra- and extravascular hemolysis, it is a *clinical process*, not a definitive morphological finding [1]. Many other conditions (e.g., PNH, transfusion reactions) also cause intravascular hemolysis. * **C. Splenomegaly:** This is typically **absent** in G6PD deficiency because the hemolysis is episodic and acute. Splenomegaly is more characteristic of chronic hemolytic anemias like Hereditary Spherocytosis. * **D. Hemoglobinuria:** This is a consequence of severe intravascular hemolysis (oxidized heme filtering into urine) [1]. While common during a crisis, it is non-specific and seen in various other hemolytic states. **High-Yield Clinical Pearls for NEET-PG:** * **Heinz Bodies:** Visible only with **supravital stains** (e.g., Crystal Violet or Methyl Violet), not on routine Leishman/Giemsa stains. * **Blister Cells:** RBCs where the hemoglobin is pushed to one side; these are precursors to bite cells. * **Diagnostic Timing:** Never perform the G6PD enzyme assay during an acute hemolytic crisis, as reticulocytes (which have higher enzyme levels) can produce a **false-normal result**. Test 6–8 weeks after the episode. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 642-643.

Question 516: What is the level of soluble transferrin receptor in iron deficiency anemia?

A. Increased (Correct Answer)
B. Decreased
C. Normal
D. None

Explanation: **Explanation:** **1. Why the Correct Answer (A) is Right:** Soluble Transferrin Receptor (sTfR) is a truncated form of the membrane-bound transferrin receptor found on the surface of erythroid precursor cells. Its concentration in the serum is directly proportional to the total number of transferrin receptors on these cells [1]. When intracellular iron levels drop—as seen in **Iron Deficiency Anemia (IDA)**—the cell upregulates the expression of transferrin receptors to capture as much iron as possible from the circulation [1]. Consequently, the level of sTfR increases significantly. This makes sTfR a sensitive marker for iron-deficient erythropoiesis. **2. Why Other Options are Wrong:** * **B. Decreased:** sTfR levels decrease in conditions where erythropoiesis is suppressed (e.g., aplastic anemia or chronic renal failure) or in states of iron overload (e.g., hemochromatosis), where cells downregulate receptors. * **C. Normal:** sTfR levels remain **normal in Anemia of Chronic Disease (ACD)**. This is the most critical clinical distinction, as ACD is characterized by iron sequestration rather than a true systemic deficit [1]. **3. NEET-PG High-Yield Pearls:** * **The "Gold Standard" Utility:** The sTfR assay is the most reliable test to differentiate between **IDA (Increased sTfR)** and **ACD (Normal sTfR)**, especially when ferritin levels are falsely elevated due to inflammation (as ferritin is an acute-phase reactant). * **sTfR-Ferritin Index:** A high index (sTfR/log Ferritin) is highly suggestive of IDA. * **Independence:** Unlike ferritin, sTfR levels are **not** affected by systemic inflammation, infection, or liver disease, making it a "cleaner" marker for marrow iron status. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 657-658.

Question 517: What is the main diagnostic test for hereditary spherocytosis?

A. Osmotic fragility (Correct Answer)
B. Bone marrow study
C. Hemoglobin electrophoresis
D. Mutation study

Explanation: **Explanation:** **Hereditary Spherocytosis (HS)** is an autosomal dominant disorder caused by defects in red blood cell (RBC) membrane proteins (most commonly **Ankyrin**, followed by Spectrin) [2]. These defects lead to a loss of membrane surface area, forcing the RBCs to assume a spherical shape (spherocytes) rather than a biconcave disc [2]. 1. **Why Osmotic Fragility is correct:** Spherocytes have a **decreased surface-area-to-volume ratio**. Because they are already "puffed up," they have very little capacity to expand when placed in hypotonic saline solutions. Consequently, they lyse at higher concentrations of saline compared to normal cells, resulting in **increased osmotic fragility** [1]. While the *Eosin-5-maleimide (EMA) binding test* (flow cytometry) is now considered the gold standard for accuracy, the Osmotic Fragility Test remains the classic diagnostic mainstay in exams [1]. 2. **Why other options are incorrect:** * **Bone marrow study:** Shows erythroid hyperplasia (a non-specific finding in all hemolytic anemias) but is not diagnostic for HS. * **Hemoglobin electrophoresis:** Used to diagnose hemoglobinopathies (e.g., Sickle Cell, Thalassemia), not membrane defects. * **Mutation study:** While it can identify the specific protein defect (Ankyrin/Spectrin), it is expensive, complex, and not required for routine diagnosis. **High-Yield Clinical Pearls for NEET-PG:** * **Peripheral Smear:** Shows spherocytes (small, dark RBCs lacking central pallor) and polychromasia (reticulocytosis) [1]. * **Lab Hallmark:** Increased **MCHC** (>36 g/dL) is a highly characteristic finding. * **Clinical Triad:** Anemia, Jaundice, and Splenomegaly [1]. * **Complications:** Pigmented gallstones (calcium bilirubinate) and aplastic crisis (associated with **Parvovirus B19**) [1]. * **Treatment:** Splenectomy is the definitive treatment for moderate to severe cases (postpone until age >5 to reduce sepsis risk) [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 597-598. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 640-641.

Question 518: Total iron binding capacity is increased in which of the following conditions?

A. Iron deficiency anaemia (Correct Answer)
B. Anaemia of chronic disease
C. Sideroblastic anaemia
D. Beta-thalassemia

Explanation: **Explanation:** **Total Iron Binding Capacity (TIBC)** is a functional measurement of the amount of **Transferrin** available in the blood to bind iron [1]. Transferrin is synthesized by the liver, and its production is inversely related to the body's iron stores. 1. **Why Iron Deficiency Anaemia (IDA) is correct:** In IDA, the body’s iron stores (Ferritin) are depleted. In a compensatory attempt to capture as much iron as possible from the gut and transport it to the bone marrow, the liver increases the synthesis of Transferrin. Consequently, the TIBC increases. This is the hallmark of IDA: **Low Serum Iron + High TIBC.** 2. **Why the other options are incorrect:** * **Anaemia of Chronic Disease (ACD):** Driven by Hepcidin, iron is "trapped" within macrophages [2]. The body perceives an abundance of iron (high Ferritin), leading the liver to decrease Transferrin production. Thus, **TIBC is decreased** in ACD [4]. * **Sideroblastic Anaemia & Beta-Thalassemia:** These are iron-overload states (due to ineffective erythropoiesis or frequent transfusions) [3]. When iron stores are high, Transferrin synthesis is suppressed, leading to a **decreased TIBC** and high Transferrin saturation. **High-Yield Clinical Pearls for NEET-PG:** * **Transferrin Saturation:** Calculated as (Serum Iron / TIBC) × 100. It is decreased in IDA (<15%) and increased in Thalassemia/Sideroblastic anaemia. * **Soluble Transferrin Receptor (sTfR):** This is the most sensitive marker to differentiate IDA (increased) from ACD (normal). * **Mentzer Index:** (MCV/RBC count) <13 suggests Thalassemia trait; >13 suggests IDA. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 657-658. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 658-659. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 587-588. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 660-662.

Question 519: Which of the following is a common blood transfusion reaction?

A. Febrile nonhemolytic transfusion reaction (Correct Answer)
B. Hemolysis
C. Transmission of infections
D. Electrolyte imbalance

Explanation: **Explanation:** **Correct Answer: A. Febrile nonhemolytic transfusion reaction (FNHTR)** FNHTR is the **most common** adverse reaction associated with the transfusion of blood products. It is defined as a rise in temperature of $\geq 1^\circ\text{C}$ during or shortly after transfusion, without any other explainable cause. * **Mechanism:** It is primarily caused by **preformed cytokines** (like IL-1, IL-6, and TNF-$\alpha$) that accumulate in the stored blood component or by recipient antibodies reacting against donor white blood cells (HLA antigens). * **Prevention:** The incidence has significantly decreased due to the routine use of **leukoreduction** (filtering out WBCs before storage). **Incorrect Options:** * **B. Hemolysis:** Acute hemolytic reactions (usually due to ABO incompatibility) are life-threatening but **rare** due to strict cross-matching protocols [1]. * **C. Transmission of infections:** With modern nucleic acid testing (NAT) and rigorous screening for HIV, Hepatitis B, and C, the risk of transfusion-transmitted infections is now extremely low. * **D. Electrolyte imbalance:** While complications like hyperkalemia or hypocalcemia (citrate toxicity) can occur, they are typically seen only in **massive transfusions** and are not common in routine single-unit transfusions. **NEET-PG High-Yield Pearls:** * **Most common overall reaction:** Febrile nonhemolytic transfusion reaction. * **Most common cause of transfusion-related death:** TRALI (Transfusion-Related Acute Lung Injury). * **Most common infectious risk:** Bacterial contamination (especially in **Platelets**, as they are stored at room temperature). * **Management of FNHTR:** Stop transfusion, rule out hemolysis, and administer antipyretics (Acetaminophen). [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 673-674.

Question 520: How does vitamin B12 and folic acid supplementation improve megaloblastic anemia?

A. Erythroid hyperplasia
B. Increased iron absorption
C. Increased hemoglobin production
D. Increased DNA synthesis in bone marrow (Correct Answer)

Explanation: ### Explanation **1. Why the Correct Answer is Right:** Vitamin B12 and Folic acid are essential co-factors for **DNA synthesis** [2]. Specifically, Vitamin B12 acts as a cofactor for the enzyme *methionine synthase*, which converts homocysteine to methionine [4]. During this reaction, methyl-tetrahydrofolate (methyl-THF) is converted to THF, which is then used to produce **dTMP (deoxythymidine monophosphate)**—a critical building block for DNA [2]. In megaloblastic anemia, a deficiency in these vitamins leads to **impaired DNA synthesis** while RNA and protein synthesis remain unaffected [2]. This results in **nuclear-cytoplasmic asynchrony** (the nucleus remains immature while the cytoplasm matures), leading to large, fragile megaloblasts in the bone marrow [4]. Supplementation restores the pool of thymidine, allowing DNA replication to proceed normally, thereby correcting the ineffective erythropoiesis [3]. **2. Why the Incorrect Options are Wrong:** * **A. Erythroid hyperplasia:** This is a *feature* of megaloblastic anemia (due to increased EPO stimulation in response to anemia), not the mechanism of improvement. Supplementation actually *reverses* the pathological hyperplasia [3]. * **B. Increased iron absorption:** This is the mechanism for treating Iron Deficiency Anemia (Vitamin C helps here, not B12/Folate). * **C. Increased hemoglobin production:** While Hb levels eventually rise, this is a secondary effect. Hemoglobin synthesis is primarily dependent on iron and protoporphyrin, not B12/Folate. **3. High-Yield Clinical Pearls for NEET-PG:** * **The Folate Trap:** Vitamin B12 deficiency leads to folate being "trapped" in the methyl-THF form, causing a functional folate deficiency [4]. * **Neurological Symptoms:** Only B12 deficiency causes Subacute Combined Degeneration (SCD) of the spinal cord due to impaired myelin synthesis (accumulation of methylmalonic acid) [1]. **Never** treat B12 deficiency with folate alone, as it may worsen neurological damage. * **Lab Findings:** Look for **Hypersegmented neutrophils** (earliest sign) [5] and increased levels of **Homocysteine** (in both) and **Methylmalonic acid (MMA)** (only in B12 deficiency). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 130-131. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 656-657. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 594-595. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 654-655. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 654.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free